A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Genentech, Inc.
- Study ID
- NCT00097188
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Not accepted
Interventions
- rituximab — DRUG
Study Details
This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS.
Key Dates
- Start date
- Dec 31, 2004
- Status verified
- Feb 2014
- Completion
- Dec 31, 2006
Study Design
- Enrollment
- 104 participants (actual)
- Primary purpose
- TREATMENT
Primary Outcome Measure
To investigate the efficacy of rituximab compared with placebo, as measured by MRI scans of the brain for the total number of lesions observed, and to evaluate the safety and tolerability of rituximab in subjects with RRMS.
Locations (31)
Find similar trials in Phoenix, AZ
By condition
By specialty
Related Studies
- Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)Recruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland
- Serum Auto-Antibodies in Neurological DiseasesEnrolling By Invitation · University of California, Davis · Sacramento, California
- Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous SystemRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- NARCOMS Registry: A Multiple Sclerosis RegistryRecruiting · University of Texas Southwestern Medical Center · Dallas, Texas